ArticleOncotarget2018

Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors.

Satoshi Tamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.